Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer

BACKGROUND: Colorectal cancer (CRC) is the third commonly diagnosed cancer with a high risk of death. After curative surgery, 40% of patients will have metastases or develop recurrence. Therefore, chemotherapy is significantly responsible as the major therapy method. However, chemoresistance is foun...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhuo, Yu, Miao, Fei, Bingyuan, Sun, Jing, Wang, Dongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430989/
https://www.ncbi.nlm.nih.gov/pubmed/30936724
http://dx.doi.org/10.2147/OTT.S192923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430989/
https://www.ncbi.nlm.nih.gov/pubmed/30936724
http://dx.doi.org/10.2147/OTT.S192923

Ejemplares similares